A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Acronyms BE BRIGHT
- Sponsors UCB Biopharma
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.
- 01 Aug 2018 New trial record
- 26 Jul 2018 According to an UCB media release, the company is planning to start the trial by the end of 2018.